|
1
|
Eggermont AM, Spatz A and Robert C:
Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rastrelli M, Alaibac M, Stramare R,
Chiarion Sileni V, Montesco MC, Vecchiato A, Campana LG and Rossi
CR: Melanoma m (zero): Diagnosis and therapy. ISRN Dermatol.
2013:6161702013.PubMed/NCBI
|
|
3
|
Gandini S, Autier P and Boniol M: Reviews
on sun exposure and artificial light and melanoma. Prog Biophys Mol
Biol. 107:362–366. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Christenson LJ, Borrowman TA, Vachon CM,
Tollefson MM, Otley CC, Weaver AL and Roenigk RK: Incidence of
basal cell and squamous cell carcinomas in a population younger
than 40 years. JAMA. 294:681–690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Birch-Johansen F, Jensen A, Mortensen L,
Olesen AB and Kjær SK: Trends in the incidence of nonmelanoma skin
cancer in Denmark 1978–2007: Rapid incidence increase among young
Danish women. Int J Cancer. 127:2190–2198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rastrelli M, Tropea S, Pigozzo J, Bezzon
E, Campana LG, Stramare R, Alaibac M and Rossi CR: Melanoma m1:
Diagnosis and therapy. In Vivo. 28:273–285. 2014.PubMed/NCBI
|
|
7
|
Panasiti V, Curzio M, Roberti V, Lieto P,
Devirgiliis V, Gobbi S, Naspi A, Coppola R, Lopez T, di Meo N, et
al: Metastatic volume: An old oncologic concept and a new
prognostic factor for stage IV melanoma patients. Dermatology.
227:55–61. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors
for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Abeni D, Boyle P and Melchi CF: Meta-analysis of risk factors
for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer.
41:28–44. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Zanetti R, Masini C, Boyle P and Melchi CF: Meta-analysis of
risk factors for cutaneous melanoma: III. Family history, actinic
damage and phenotypic factors. Eur J Cancer. 41:2040–2059. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsao H, Chin L, Garraway LA and Fisher DE:
Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Colombino M, Capone M, Lissia A, Cossu A,
Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, et
al: BRAF/NRAS mutation frequencies among primary tumors and
metastases in patients with melanoma. J Clin Oncol. 30:2522–2529.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Platz A, Egyhazi S, Ringborg U and Hansson
J: Human cutaneous melanoma; a review of NRAS and BRAF mutation
frequencies in relation to histogenetic subclass and body site. Mol
Oncol. 1:395–405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van Raamsdonk CD, Bezrookove V, Green G,
Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS and Bastian
BC: Frequent somatic mutations of GNAQ in uveal melanoma and blue
naevi. Nature. 457:599–602. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Navarini-Meury AA and Conrad C: Melanoma
and innate immunity - Active inflammation or just erroneous
attraction? Melanoma as the source of leukocyte-attracting
chemokines. Semin Cancer Biol. 19:84–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iwasaki A and Medzhitov R: Toll-like
receptor control of the adaptive immune responses. Nat Immunol.
5:987–995. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Medzhitov R: Toll-like receptors and
innate immunity. Nat Rev Immunol. 1:135–145. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Burns EM and Yusuf N: Toll-like receptors
and skin cancer. Front Immunol. 5:1352014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akira S and Hemmi H: Recognition of
pathogen associated molecular patterns by TLR family. Immunol Lett.
85:85–95. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akira S and Takeda K: Toll-like receptor
signaling. Nat Rev Immunol. 4:499–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eiró N, Ovies C, Fernandez-Garcia B,
Álvarez-Cuesta CC, González L, González LO and Vizoso FJ:
Expression of TLR 3, 4, 7 and 9 in cutaneous malignant melanoma:
Relationship with clinicopathological characteristics and
prognosis. Arch Dermatol Res. 305:59–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyake K: Innate immune sensing of
pathogens and danger signals by cell surface Toll-like receptors.
Semin Immunol. 19:3–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Häcker H, Mischak H, Miethke T, Liptay S,
Schmid R, Sparwasser T, Heeg K, Lipford GB and Wagner H:
CpG-DNA-specific activation of antigen-presenting cells requires
stress kinase activity and is preceded by non-specific endocytosis
and endosomal maturation. EMBO J. 17:6230–6240. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seki E and Brenner DA: Toll-like receptors
and adaptor molecules in liver disease: Update. Hepatology.
48:322–335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moynagh PN: TLR signaling and activation
of IRFs: Revisiting old friends from the NF-kappaB pathway. Trends
Immunol. 26:469–476. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ermertcan AT, Öztürk F and Gündüz K:
Toll-like receptors and skin. J Eur Acad Dermatol Venereol.
25:997–1006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saint-Jean M, Knol AC, Nguyen JM, Khammari
A and Dréno B: TLR expression in human melanoma cells. Eur J
Dermatol. 21:899–905. 2011.PubMed/NCBI
|
|
28
|
Sato Y, Goto Y, Narita N and Hoon DS:
Cancer cells expressing toll-like receptors and the tumor
microenvironment. Cancer Microenviron. 2(Suppl 1): 205–214. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang B, Zhao J, Unkeless JC, Feng ZH and
Xiong H: TLR signaling by tumor and immune cells: A double-edged
sword. Oncogene. 27:218–224. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valins W, Amini S and Berman B: The
expression of Toll-like receptors in dermatological diseases and
the therapeutic effect of current and newer topical Toll-like
receptor modulators. J Clin Aesthet Dermatol. 3:20–29. 2010.
|
|
31
|
El-Omar EM, Ng MT and Hold GL:
Polymorphisms in Toll-like receptor genes and risk of cancer.
Oncogene. 27:244–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maire C, Vercambre-Darras S and Desmedt E:
Diagnosis of melanoma. Rev Prat. 64:61–68. 2014.(In French).
PubMed/NCBI
|
|
33
|
Bordignon M, Bargagli E, Agostini C,
Cinetto F, Baldo V, Alaibac M and Rottoli P: TLR7 Gln11Leu single
nucleotide polymorphism in patients with sarcoidosis. Sarcoidosis
Vasc Diffuse Lung Dis. 30:157–161. 2013.PubMed/NCBI
|
|
34
|
Wong JG, Toole JW, Demers AA, Musto G and
Wiseman MC: Topical 5% imiquimod in the treatment of lentigo
maligna. J Cutan Med Surg. 16:245–249. 2012.PubMed/NCBI
|
|
35
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kutikhin AG: Association of polymorphisms
in TLR genes and in genes of the Toll-like receptor signaling
pathway with cancer risk. Hum Immunol. 72:1095–1116. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tengroth L, Millrud CR, Kvarnhammar AM,
Kumlien Georén S, Latif L and Cardell LO: Functional effects of
Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in
nasal epithelial cells. PLoS One. 9:e982392014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Yang H, Barnie PA, Yang P, Su Z,
Chen J, Jiao Z, Lu L, Wang S and Xu H: The expression of Toll-like
receptor 8 and its relationship with VEGF and Bcl-2 in cervical
cancer. Int J Med Sci. 11:608–613. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ridnour LA, Cheng RY, Switzer CH, Heinecke
JL, Ambs S, Glynn S, Young HA, Trinchieri G and Wink DA: Molecular
pathways: Toll-like receptors in the tumor microenvironment - poor
prognosis or new therapeutic opportunity. Clin Cancer Res.
19:1340–1346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Krieg AM: Antitumor applications of
stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
Curr Oncol Rep. 6:88–95. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aspord C, Tramcourt L, Leloup C, et al:
Imiquimod inhibits melanoma development by promoting pDC cytotoxic
functions and impeding tumor vascularization. J Invest Dermatol.
134:2551–2561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang D, Precopio M, Lan T, Yu D, Tang JX,
Kandimalla ER and Agrawal S: Antitumor activity and immune response
induction of a dual agonist of Toll-like receptors 7 and 8. Mol
Cancer Ther. 9:1788–1797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang J, Kobayashi M, Han M, Choi S, Takano
M, Hashino S, Tanaka J, Kondoh T, Kawamura K and Hosokawa M: MyD88
is involved in the signaling pathway for Taxol-induced apoptosis
and TNF-alpha expression in human myelomonocytic cells. Br J
Haematol. 118:638–645. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tyring S, Conant M, Marini M, Van Der
Meijden W and Washenik K: Imiquimod; an international update on
therapeutic uses in dermatology. Int J Dermatol. 41:810–816. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gupta AK, Cherman AM and Tyring SK: Viral
and nonviral uses of imiquimod: A review. J Cutan Med Surg.
8:338–352. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yates CM and Sternberg MJ: The effects of
non-synonymous single nucleotide polymorphisms (nsSNPs) on
protein-protein interactions. J Mol Biol. 425:3949–3963. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gast A, Bermejo JL, Claus R, Brandt A,
Weires M, Weber A, Plass C, Sucker A, Hemminki K, Schadendorf D and
Kumar R: Association of inherited variation in Toll-like receptor
genes with malignant melanoma susceptibility and survival. PLoS
One. 6:e243702011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Askar E, Ramadori G and Mihm S: Toll-like
receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C
virus infection. J Med Virol. 82:1859–1868. 2010. View Article : Google Scholar : PubMed/NCBI
|
